Posted on

buy mari

Mari’s non-destructive layer and node graph systems make it easy for artists to create the look they want, offering an extensive range of procedurals. The Materials system gives artists the ability to easily create less complex, higher-volume assets or quickly lay down the building blocks for their hero assets

Mari® is 3D painting without limits, combining the power and performance to handle even the most complex assets with artist-friendly 3D paint tools, that make the most of your creativity.

With an extensive Python API and full OCIO color management support, technical artists can easily automate workflows and handle color transforms. What’s more, Mari offers support for industry-standard formats like FBX, OBJ, Alembic and OpenEXR.

Procedural Workflows

With support for UDIM workflows, artists can work with hundreds of high-resolution texture maps. Its projection-based painting system allows artists to make edits to paint before committing it, preview it in context and make 2D adjustments—freeing artists from the limits of resolution and complexity.

With the ability to scale to over one million polygons for a single topology without slowing down, Mari can cope with the toughest production meshes and support thousands of textures per model via UDIMs. Artists can enjoy a streamlined look development with Mari’s shaders and paint textures with more confidence, knowing that their art will look correct in the final render.

Mari Samuelsen ist zweifelsohne eine begnadete Musikerin, die die Stücke der gut zusammengestellten Auswahl einfach klasse interpretiert. Die CD ist eine Wucht.

Return Policy on this item

All items in Music are non returnable. Learn more

Customer reviews

Aufpassen muss man beim Bestellen auf die Ausführung: die hier ebenfalls teilweise sogar sehr günstig angebotene SHM-CD war bei mir ein Import aus Japan mit japanischem Booklet. Leider wurde da nicht drauf hingewiesen, was sehr schade ist. Ob die normale CD mit zumindest englischem Booklet daherkommt, kann ich nicht sagen. Ich werde versuchen, die CD gegen ein Exemplar umzutauschen, dessen Booklet ich auch lesen kann.

GW Pharmaceuticals is the largest cannabis-focused drug developer. The company’s first drug, Sativex (which contains both tetrahydrocannabinol (THC), the cannabinoid responsible for marijuana’s “high,” and cannabidiol (CBD), which does not have intoxicating effects) is approved in multiple countries outside the U.S. for treating spasticity associated with multiple sclerosis. GW’s most successful product, the CBD drug Epidiolex, is approved in both the U.S. and Europe.

The company is profitable and enjoys solid revenue growth. Medical cannabis extraction in Europe, Australia, and Latin America presents great growth opportunities. Its top opportunity now, though, is the second phase of Canada’s recreational marijuana market, which allows the sale of cannabis derivatives such as vapes and edibles.

Canopy Growth serves the Canadian medical and recreational marijuana markets and distributes medical cannabis to international markets, including Germany. The biggest knock against Canopy Growth is that it can’t yet compete in the huge U.S. medical cannabis market. However, the company hopes that will change in the not-too-distant future with federal cannabis reform in the U.S.

GW Pharmaceuticals

Investors who opt to buy individual medical marijuana stocks can choose Canadian or U.S. companies. Because marijuana is currently illegal at the federal level in the U.S., companies with operations that violate those laws can’t be listed on the major U.S. stock exchanges. However, their stocks are traded on less-regulated over-the-counter (OTC) markets and, in some cases, on smaller Canadian stock exchanges.

Canopy Growth (NASDAQ:CGC)

Innovative Industrial Properties currently owns properties that are leased to tenants in 17 states. The company’s growth prospects include opportunities to build its customer base in the states where it already operates and to expand into additional states.

Innovative Industrial Properties (NYSE:IIPR)